The ECM is a well-known driver of fibrosis [34], and a reduction in liver serotonin receptor 2A has been shown to ameliorate hepatic steatosis, indicating its potential role in the progression and treatment of MASLD [35]. This evidence concerns the gene HTR2A and metabolic dysfunction-associated steatotic liver disease.